RPE cell transplant therapy shows signs of retinal regeneration in early results
A patient enrolled in a phase 1/2a study of OpRegen for dry age-related macular degeneration showed signs of retinal tissue regeneration, according to a press release.
After retinal pigment epithelium cell transplantation with Lineage Cell Therapeutics’ lead product candidate in one patient of 17 so far enrolled, geographic atrophy was 25% smaller at 9 months than at baseline. In the next 6 months, the area grew approximately 50% slower than its historical rate, according to the release.
The data were originally observed by an independent external advisor using multiple imaging technologies. The data were confirmed by additional experts in the retinal imaging field, the release said.
“Our team has independently reviewed these data as part of our ongoing collaborative efforts with Lineage, and I think it is evidence of a partially restorative effect in this patient,” Michael S. Ip, MD, chief of vitreoretinal surgery service, Doheny Eye Centers, UCLA, said. “We have observed apparent RPE regeneration on detailed review of imaging and will look forward to reviewing additional patient data from the OpRegen clinical trial to determine the reproducibility and durability of this unexpected finding.”